Andres Felipe Leal

Potential Targeting Mechanisms for Bone-Directed Therapies; International Journal of Molecular Sciences; (2024).

Glycosaminoglycans in mucopolysaccharidoses and other disorders; Advances in Clinical Chemistry; (2024).

Current Strategies for Increasing Knock-In Efficiency in CRISPR/Cas9-Based Approaches; International Journal of Molecular Sciences; (2024).

The landscape of CRISPR/Cas9 for inborn errors of metabolism; Molecular Genetics and Metabolism; (2023).

Molecular Trojan Horses for treating lysosomal storage diseases; Molecular Genetics and Metabolism; (2023).

Iron oxide-coupled CRISPR-nCas9-based genome editing assessment in mucopolysaccharidosis IVA mice; Molecular Therapy Methods and Clinical Development; (2023).

Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks; International Journal of Molecular Sciences; (2023).

CRISPR/nCas9-Based Genome Editing on GM2 Gangliosidoses Fibroblasts via Non-Viral Vectors; International Journal of Molecular Sciences; (2022).

Regulation of Molecular Targets in Osteosarcoma Treatment; International Journal of Molecular Sciences; (2022).

Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets; International Journal of Molecular Sciences; (2022).

Efficient CRISPR/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA; Gene Therapy; (2022).

Sphingolipids and their role in health and disease in the central nervous system; Advances in Biological Regulation; (2022).

Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles; Scientific Reports; (2022).

Magnetoliposomes as Carriers for CRISPR/nCas9-Based Gene Therapy on In Vitro Models of Mucopolysaccharidoses IVA and GM2 Gangliosidoses: Proof-of-Concept experiments; Molecular Therapy; (2022).

Hematological findings in lysosomal storage disorders: a perspective from the medical laboratory; Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine; (2022).

Genome editing on GM2 gangliosidoses fibroblasts using CRISPR/nCas9; Molecular Genetics and Metabolism; (2022).

Hematological Findings in Lysosomal Storage Disorders: A Perspective from the Medical Laboratory.; EJIFCC; (2022).

Sphingolipids and Cell Signaling: Relationship Between Health and Disease in the Central Nervous System; Unknown Source; (2021).

Recombinant hexosaminidases conjugated to magnetite nanoparticles: Alternative therapeutic treatment routes in GM2 fibroblasts; Molecular Genetics and Metabolism; (2020).

Lysosomal storage diseases: current therapies and future alternatives; Journal of Molecular Medicine; (2020).

GM2 Gangliosidosis: Clinical Features and Current Therapies; Unknown Source; (2020).

GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies; International Journal of Molecular Sciences; (2020).

GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects and Current Therapies; Unknown Source; (2020).

Differential anti-proliferative effect on K562 leukemia cells of Lippia alba (Verbenaceae) essential oils produced under diverse growing, collection and extraction conditions; Industrial Crops and Products; (2017).

Tuberculosis caused by Mycobacterium bovis in workers of bovine tuberculosis sanitation farms in Antioquia, Boyacá and Cundinamarca,Tuberculosis por Mycobacterium bovis en trabajadores de fincas en saneamiento para tuberculosis bovina, de Antioquia, Boyacá y Cundinamarca; Revista de Salud Publica; (2016).